Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • idiopathic pulmonary fibrosis

    - PMLiVE

    Boehringer Ingelheim and CDR-Life agree on deal worth up to $570m

    The deal focuses on T cell-based therapies for autoimmune disease

    - PMLiVE

    Boehringer’s Hernexeos granted FDA accelerated approval for lung cancer patients

    Approximately 226,650 lung cancer cases are expected to be diagnosed in the US this year

    - PMLiVE

    LEO Pharma gains access to Boehringer’s skin disease drug for €90m upfront

    Spevigo is already approved in over 40 countries to treat generalised pustular psoriasis

    - PMLiVE

    Boehringer’s Spevigo recommended by NICE for generalised pustular psoriasis

    The rare form of psoriasis can lead to serious complications such as sepsis and heart failure

    - PMLiVE

    Boehringer’s nerandomilast shows lung function benefit in phase 3 IPF and PPF trials

    The candidate is currently under review for both interstitial lung diseases in the EU and US

    - PMLiVE

    Boehringer Ingelheim and Tessellate Bio enter oncology partnership worth over €500m

    The companies will focus on developing treatments for hard-to-treat ALT-positive tumours

    - PMLiVE

    Boehringer and Cue partner to advance autoimmune disease candidate in deal worth $357m

    The B cell depletion therapy has the potential to reach patients earlier in their treatment journeys

    - PMLiVE

    Boehringer Ingelheim and Salipro Biotech enter drug development partnership

    The companies will focus on targeting proteins in areas such as cardio-renal-metabolic diseases

    - PMLiVE

    World Kidney Day – Boehringer launches CKD initiative to tackle UK health inequalities

    Approximately 10% of the UK population is affected by chronic kidney disease

    - PMLiVE

    Boehringer’s nerandomilast shows promise in phase 3 pulmonary fibrosis study

    The company said it will now be submitting a new drug application for the candidate in this indication

    - PMLiVE

    Boehringer gains access to Synaffix’s ADC technology through $1.3bn licensing deal

    The Lonza company will provide access to its ADC technologies for an undisclosed number of targets

    - PMLiVE

    Boehringer Ingelheim’s Spevigo recommended by CHMP for generalised pustular psoriasis

    The chronic neutrophilic inflammatory disease can lead to severe complications, including multisystem organ failure

    Subscribe to our email news alerts

    Latest content

    Latest intelligence

    Quick links